Clinical Best Solutions Sp. z o.o. S.K.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research at Clinical Best Solutions Sp. z o.o. S.K. focuses on atherosclerotic cardiovascular disease, heart failure subtypes, and lipid abnormalities, aiming to test new therapies that lower cardiovascular risk and improve outcomes.
- Atherosclerosis and plaque burden
- Heart failure with reduced ejection fraction
- Elevated lipoprotein(a) levels
- Hyperlipidemia and triglyceride reduction
- Cardiovascular event prevention
With 53 investigators, the site evaluates innovative agents that may reduce major adverse cardiac events and support heart health.
Respiratory Tract Diseases
Trials address chronic obstructive pulmonary disease and asthma, testing treatments that aim to decrease exacerbations and improve lung function for patients with severe respiratory conditions.
- Chronic obstructive pulmonary disease (COPD)
- Asthma control and bronchoconstriction
- Exacerbation rate reduction
- Triple inhaler therapy assessment
- Long‑term safety of novel bronchodilators
The site’s multidisciplinary team contributes to advancing respiratory care for high‑risk individuals.
Skin and Connective Tissue Diseases
Research includes atopic dermatitis, psoriasis, and palmoplantar pustulosis, with objectives to evaluate new topical or systemic agents that lessen skin inflammation and enhance quality of life.
- Moderate‑to‑severe atopic dermatitis
- Plaque psoriasis severity
- Genital psoriasis treatment
- Palmoplantar pustulosis management
- Skin lesion scoring (EASI, PASI)
Clinical Best Solutions provides a platform for evaluating innovative dermatologic therapies.
Nervous System Diseases
The center conducts studies on epilepsy, seizures, and multiple sclerosis, seeking to improve seizure control and disease‑modifying outcomes through novel agents.
- Focal‑onset seizures
- Refractory epilepsy
- Primary generalized tonic‑clonic seizures
- Relapsing multiple sclerosis
- Seizure frequency reduction
Leveraging a skilled neurologic cohort, the site advances therapeutic options for patients with challenging neurological disorders.
Musculoskeletal Diseases
Investigations target chronic low‑back pain and related musculoskeletal conditions, aiming to assess pain‑relieving strategies when conventional non‑opioid options have failed.
- Chronic non‑specific low back pain
- Pain intensity measurement
- Adjunctive analgesic therapies
- Safety of novel pain agents
- Functional improvement outcomes
The site’s expertise supports the development of safer, effective treatments for persistent musculoskeletal pain.
Immune System Diseases
Studies explore autoimmune conditions such as ulcerative colitis and Graves’ disease, evaluating biologics and small molecules that aim to modulate immune activity and achieve remission.
- Ulcerative colitis remission
- Graves’ disease management
- Immune‑modulating biologics
- Inflammatory bowel disease outcomes
- Safety of long‑term immunotherapy
With a robust clinical infrastructure, the site contributes to advancing care for immune‑mediated disorders.
Neoplasms
Oncology trials focus on metastatic prostate cancer and other advanced tumors, testing combination regimens that may extend progression‑free survival and improve survival metrics.
- Metastatic castration‑resistant prostate cancer
- Hormone‑sensitive prostate cancer
- Combination therapy with androgen‑targeted agents
- Radiographic progression‑free survival
- Safety of novel oncology compounds
The facility’s oncology team collaborates to bring cutting‑edge cancer treatments to patients.
Digestive System Diseases
Research includes ulcerative colitis and other inflammatory bowel conditions, with goals to assess efficacy of new agents in achieving clinical remission and mucosal healing.
- Moderately to severely active ulcerative colitis
- Clinical remission rates
- Mucosal healing assessment
- Biologic and small‑molecule therapies
- Long‑term safety monitoring
The site’s gastroenterology specialists support rigorous evaluation of innovative IBD treatments.
Nutritional and Metabolic Diseases
Trials address type 2 diabetes, obesity, and metabolic syndrome, testing agents that improve glycemic control, promote weight loss, and reduce cardiovascular risk factors.
- Type 2 diabetes glycemic management
- Obesity and overweight interventions
- Weight‑loss efficacy studies
- Metabolic risk reduction
- Comparative effectiveness versus standard therapy
Clinical Best Solutions engages metabolic experts to explore therapies that tackle the growing burden of metabolic disease.
Congenital, Hereditary, and Neonatal Diseases
Investigations target rare hereditary conditions, aiming to evaluate safety and potential benefits of emerging treatments for patients with genetic disorders.
- Rare hereditary disease cohorts
- Safety profiling of novel agents
- Clinical benefit assessment
- Genotype‑guided therapeutic approaches
- Long‑term outcome monitoring
The site’s commitment to rare disease research expands therapeutic options for underserved populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 13 therapeutic areas and 15 of 117 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 113 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
- 1AstraZeneca AB4active
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.10trials
lock +19 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinical Best Solutions Sp. z o.o. S.K.
lock Showing 1 of 87 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4) | Xenon Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 117 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Maridebart Cafraglutide | 4 | Unknown | 2023-03-10 | 2025-10-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.